Method of toxicological evaluation, method of toxicological screening and associated system

Patent metadata

Field	Value
Publication number	US-9448226-B2
Application number	US-201113696861-A
Country	US
Kind code	B2
Filing date	May 12, 2011
Priority date	May 12, 2010
Publication date	Sep 20, 2016
Grant date	Sep 20, 2016

Abstract

The present invention relates to a method of toxicological evaluation of a candidate substance on at least one tissue or organ, characterized in that it comprises the steps of: (a) obtaining a bioartificial tissue or organ by simulation or modelling of the metabolic activity of said tissue or organ by at least one bioreactor; (b) exposure of said bioartificial tissue or organ to said substance; (c) observation of the metabolic response of the bioartificial tissue or organ and acquisition without a priori of an associated multidimensional data set; (d) identification by means of a method of multivariate statistical analysis of the components of the multidimensional data set which are quantitatively correlated with predetermined variables; (e) generation of a predictive model on the basis of the components of the data set that are actually retained; (f) testing of the predictive nature of said model by at least one statistical method of estimating reliability; (g) identification of the metabolic response of the bioartificial tissue or organ in the form of biomarkers associated with the components of the data set that are adopted for the model. The present invention also relates to a method of toxicological screening and to a system for this purpose.

First claim

The invention claimed is:

1. A method of toxicological evaluation of a candidate substance on at least one tissue or organ, comprising the steps of:
(a) obtaining a bioartificial tissue or organ by simulation or modeling of the metabolic activity of said tissue or organ by at least one bioreactor;
(b) exposing said bioartificial tissue or organ to said substance by introducing said substance inside the at least one bioreactor during said at least one bioreactor functioning;
(c) observing the metabolic response of the bioartificial tissue or organ and acquiring, without an a priori method, an associated multidimensional data set;
(d) identifying by means of a method of multivariate statistical analysis the components of the multidimensional data set which are quantitatively correlated with predetermined variables;
(e) generating a predictive model, consisting of a function between the predetermined variables and the components of the data set actually selected, on the basis of the components of the data set actually selected;
(f) testing of the predictive nature of said model by at least one statistical method of estimating reliability; and
(g) identifying the metabolic response of the bioartificial tissue or organ in the form of biomarkers associated with the components of the data set selected for the model.

2. The method of claim 1 wherein the method of multivariate analysis used in step (d) is a partial least squares discriminant analysis (PLS-DA).

3. The method of claim 1 wherein step (d) is preceded by a step (d1) of locating and eliminating aberrant points in said multidimensional data set.

4. The method of claim 3 wherein step (d1) comprises an unsupervised principal component analysis (PCA).

5. The method of claim 1 wherein one of the statistical methods for estimating reliability used in step (d) is cross-validation.

6. The method of claim 1 wherein one of the statistical methods for estimating reliability used in step (d) is validation by the null hypothesis.

7. The method of claim 1 wherein one of the statistical methods for estimating reliability used in step (d) comprises the calculation of the area under a receiver operating characteristic (ROC) curve.

8. The method of claim 1 wherein the predetermined variables used in step (d) are selected from the culture conditions, the cell type of the bioartificial tissue or organ, the type of said substance, and its amount.

9. The method of claim 1 wherein step (c) is carried out by at least one analytical chemistry technique selected from the techniques of the group comprising proton NMR spectroscopy, carbon NMR spectroscopy, mass spectrometry, gas chromatography, liquid chromatography and multiplexed detection methods.

10. The method of claim 1 wherein step (c) is carried out in the culture medium exiting the bioreactor in order to observe the extracellular metabolic response.

11. The method of claim 1 wherein step (c) is carried out on cell pellets in order to observe the intracellular endogenous metabolic response.

12. The method of claim 1 further comprising a step (h) of obtaining a specific toxicity signature of said substance from the list of biomarkers obtained in step (g).

13. The method of claim 1 further comprising a step (i) in which a bank of markers and/or toxicity signatures is created using the information obtained during the preceding steps.

14. A method of toxicological screening of a candidate substance on at least one tissue or organ, comprising the steps of:
(a) obtaining a bioartificial tissue or organ by simulation or modeling of the metabolic activity of said tissue or organ by at least one bioreactor;
(b) exposing said bioartificial tissue or organ to said substance by introducing said substance inside the at least one bioreactor during said at least one bioreactor functioning;
(c) observing the metabolic response of the bioartificial tissue or organ and acquiring, without an a priori method, an associated multidimensional data set;
(d) identifying by means of a method of multivariate statistical analysis the components of the multidimensional data set which are quantitatively correlated with predetermined variables;
(e) generating a predictive model, consisting of a function between the predetermined variables and the components of the data set actually selected, on the basis of the components of the data set actually selected;
(f) testing of the predictive nature of said model by at least one statistical method of estimating reliability;
(g) identifying the metabolic response of the bioartificial tissue or organ in the form of biomarkers associated with the components of the data set selected for the model;
(h) obtaining a specific toxicity signature of said substance from the list of biomarkers obtained in step (g);
(i) comparing the biomarkers and/or the specific toxicity signature with a bank of markers and/or toxicity signatures, so as to identify said substance.

15. A method of toxicological screening of a candidate substance on at least one tissue or organ, comprising the steps of:
(a) obtaining a bioartificial tissue or organ by simulation or modeling of the metabolic activity of said tissue or organ by at least one bioreactor;
(b) exposing said bioartificial tissue or organ to said substance by introducing said substance inside the at least one bioreactor during said at least one bioreactor functioning;
(c) observing the metabolic response of the bioartificial tissue or organ and acquiring, without an a priori method, an associated multidimensional data set;
(d) identifying by means of a method of multivariate statistical analysis the components of the multidimensional data set which are quantitatively correlated with predetermined variables;
(e) generating a predictive model, consisting of a function between the predetermined variables and the components of the data set actually selected, on the basis of the components of the data set actually selected;
(f) testing of the predictive nature of said model by at least one statistical method of estimating reliability;
(g) identifying the metabolic response of the bioartificial tissue or organ in the form of biomarkers associated with the components of the data set selected for the model;
(h) obtaining a specific toxicity signature of said substance from the list of biomarkers obtained in step (g);
(i) comparing the biomarkers and/or the specific toxicity signature with a bank of markers and/or toxicity signatures, so as to identify said substance wherein said bank of markers and/or toxicity signatures is established by the implementation of the method according to claim 13 .

16. A system comprising at least one bioreactor, means of data processing and a device for detecting biomarkers, wherein the system is able to implement the method of toxicological evaluation according to claim 1 .

17. A system comprising at least one bioreactor, means of data processing, means of data storage, and a device for detecting biomarkers, wherein the system is able to implement the method of toxicological screening according to claim 14 .

18. A system comprising at least one bioreactor, means of data processing, means of data storage, and a device for detecting biomarkers, wherein the system is able to implement the method of toxicological screening according to claim 15 .

Assignees

• Dumas Marc-Emmanuel
• Leclerc Eric
• Shintu Laetitia
• Baudoin Regis
• Legallais Cécile
• Toulhoat Pierre
• Brochot Céline
• Univ Tech De Compiegne—Utc
• Centre Nat De La Rech Scient (Cnrs)
• Ecole Normale Superieure Lyon
• Inst Nat De L'Environment Ind Et Des Risques

Inventors

• Dumas Marc-Emmanuel
• Leclerc Eric
• Shintu Laetitia
• Baudoin Regis
• Legallais Cécile
• Toulhoat Pierre
• Brochot Céline

Classifications

• G01N33/5088

  of vertebrates · CPC title

• G01N33/5041

  involving analysis of members of signalling pathways · CPC title

• G16C20/30

  Prediction of properties of chemical compounds, compositions or mixtures · CPC title

• G16C20/70

  Machine learning, data mining or chemometrics · CPC title

• G01N33/5014 Primary

  for testing toxicity · CPC title